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Abstract
Background: To assess the impact of volumetric-modulated arc therapy (VMAT) compared with 3D-conformal
radiotherapy (3DCRT) in patients with newly diagnosed high grade glioma in terms of toxicity, progression free
survival (PFS) and overall survival (OS).
Methods: From March 2004 to October 2014, 341 patients underwent surgery followed by concomitant and
adjuvant chemo-radiotherapy. From 2003 to 2010, 167 patients were treated using 3DCRT; starting from 2011, 174
patients underwent VMAT. The quantitative evaluation of the treatment plans was performed by means of standard
dose volume histogram analysis. Response was recorded using the Response Assessment in Neuro-Oncology
(RANO) criteria and toxicities graded according to Common Terminology Criteria for Adverse Event version 4.0.
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Results: Both techniques achieved an adequate dose conformity to the target. The median follow up time was 1.
3 years; at the last observation 76 patients (23.4 %) were alive and 249 (76.6 %) dead (16 patients were lot to
follow-up). For patients who underwent 3DCRT, the median PFS was 0.99 ± 0.07 years (CI95: 0.9–1.1 years); the 1
and 3 years PFS were, 49.6 ± 4 and 19.1 ± 3.1 %. This shall be compared, respectively, to 1.29 ± 0.13 years (CI95: 1.
01–1.5 years), 60.8 ± 3.8, and 29.7 ± 4.6 % for patients who underwent VMAT (p = 0.02). The median OS for 3DCRT
patients was 1.21 ± 0.09 years (CI95:1.03–1.3 years); 1 and 5 year OS was, 63.3 ± 3.8 and 21.5 ± 3.3 %. The
corresponding results for 3DRCT patients were 1.56 ± 0.09 years (CI95:1.37–1.74 years), 73.4 ± 3.5, 30 ± 4.6 %
respectively (p < 0.01). In both groups, prognostic factors conditioning PFS and OS were age, gender, KPS, histology
and extent of resection (EOR).
Conclusions: VMAT resulted superior to 3DCRT in terms of dosimetric findings and clinical results.
Keywords: Glioblastoma, Volumetric modulated arc therapy, Conformal therapy
Background
Surgery, followed by concomitant and adjuvant chemo-
radiotherapy with temozolomide (TMZ), represents the
standard of care for newly diagnosed glioblastoma (GB).
However, survival remains poor with a median survival
time and 3-year survival rate of 10–12 months and 6–8 %
respectively [1]. In WHO grade III glioma the outcome in
terms of progression free survival (PFS) and overall sur-
vival (OS) is better compared to GB patients but the inci-
dence of local recurrence is still considerable, above all in
the case of astrocytic tumors subtypes [2–5]. The pattern
of recurrence is almost local [6] and often the inability to
deliver a sufficient radiation dose to an adequate target
volume has been considered as one of the leading cause of
local failure [7, 8]. In order to improve local control and
survival, a clearer identification of the volume at the great-
est risk of recurrence is probably required, while the radi-
ation exposure of healthy brain tissue should be reduced
[9]. The close proximity of important normal brain struc-
ture, such as chiasma, optical nerve or brain stem, repre-
sents a limit to deliver the right dose to the right tumor
volume. The recent availability of modern high-precision
radiotherapy techniques [10–13] allows a more adequate
delivery of high doses with maximum sparing of normal
tissue. Intensity Modulated Radiation Therapy (IMRT)
has being increasingly evaluated and exploited for the
treatment of GB [14, 15]. Compared to 3D-conformal ra-
diation therapy (3DCRT), IMRT provides similar results
in terms of target coverage, but it results in a better dose
conformity to the target with a better sparing of the or-
gans at risk (OARs). RapidArc technology (Varian Medical
Systems, Palo Alto, USA) is a currently available form of
volumetric-modulated arc therapy (VMAT) that, with the
variation of gantry rotation speed, beam shaping aperture
and delivery dose rate, achieves an intensity-modulated
dose distribution. The variation of the three dynamic pa-
rameters is used to cover the planning target volume
(PTV) with clinically acceptable dose and to spare organs
at risk and normal tissues, reducing the treatment time.
However it is not yet clear if this new RT technology, com-
pared with traditional 3DCRT, might reduce the acute and
long-term neurotoxicity or could improve PFS and OS.
Based on the lack of evidence regarding the optimal
radiation therapy technique for patients with newly diag-
nosed high grade glioma (HGG), the aim of this study
was to evaluate the outcome of patients treated with dif-
ferent techniques in our institution in the last 10 years.
Dosimetric and clinical findings in terms of PFS and OS
were analyzed and compared.
Methods
Patients and procedures
The present retrospective study includes patients with
newly diagnosed glioblastoma and WHO Grade III gliomas
(anaplastic astrocytoma AA, anaplastic oligo-astrocytoma
AOA and anaplastic oligo-dendroglioma AO) treated at
our institute. All patients were treated in agreement with
the Helsinki declaration. This study is a summary of a
retrospective analysis to the treatment charts. The Humani-
tas Institute’s ethical committee does not require a formal
approval in case of retrospective study in which a formal
consent for handling patient medical data was obtained at
the time of admission according to the deliberation of the
national agency for clinical studies of 2008. All patients
underwent surgery plus concomitant radiotherapy and
TMZ chemotherapy followed by adjuvant TMZ according
to the Stupp’s scheme [1].
Surgical resection was performed with the aid of intra-
operative neurophysiological monitoring and brain map-
ping techniques with the aim to maximize resection
respecting eloquent areas. Patients underwent preopera-
tive baseline magnetic resonance imaging (MRI) studies,
functional MR imaging (fMRI), and diffusion tensor im-
aging (DTI) with fiber tractography (DTI-FT). Volumetric
scan analysis was used for defining tumor location and
volume. Tumor volume was computed on volumetric
postcontrast T1-weighted MRI scans. All patients under-
went intraoperative neurophysiological brain mapping,
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when needed, and monitoring. The craniotomy was
guided by neuronavigation system (Curve, BrainLab,
Heimstemen, Germany) and tailored to expose the cortex
corresponding to the tumor area. The lesion limits were
defined with the aid of intraoperative pre-calibrated multi-
frequency (3.75–10 MHz) convex transducer ultrasound
machine (UST-9120, footprint 20 mm, ProSound Alpha 7,
Hitachi Aloka Medical Ltd,Zurich, Switzerland). Cortical
mapping was performed to define the cortical safe-entry
zone. Subcortical brain mapping was then continued,
along with tumor resection. The extent of resection (EOR)
was assessed on volumetric MRI studies obtained within
48 h after surgery by segmentation analysis (BrainLab
Heimstemen, Germany). Complete resection (CR) was de-
fined as residual tumor volume lower than 1 cm3, subtotal
resection (SR) as residual tumor volume between 1 cm3
and 10 cm3 and partial resection (PR) as residual tumor
volume greater than 10 cm3 [16]. Within 4 weeks from
surgery, all patients underwent concurrent chemo-
radiotherapy, consisting in 60Gy/2 Gy fraction with con-
comitant administration of oral TMZ (75 mg/m2),
followed by adjuvant TMZ (200–250 mg/m2 for 5/28 days)
for about 6–8 cycles. For all patients computed tomog-
raphy (CT) scan and MRI were acquired for radiation
therapy planning. MR imaging was performed on a 1–3T
whole body system (Magnetom Verio, Siemens Medical
Solutions, Erlangen, Germany). The standard protocol in-
cluded pre-contrast T1-weighted fluid-attenuated inver-
sion recovery imaging (FLAIR) and T2-weighted 3D-
FLAIR followed by T1-weighted magnetization-prepared
rapid gradient echo (MP-RAGE) images acquired after
intravenous administration of 0.6 cm3/kg (1.0 mmol/ cm3)
Gadolinium-based contrast agent.
Target volume definition and planning optimization
To precisely delineate the extension of tumor and eventual
residual tumor after surgery, pre- and post-operative en-
hanced T1-MRI and FLAIR-MRI sequences were used and
co-registered. The procedure for target definition included
post-contrast CT scan too. Patients were placed in supine
position with arms close to the body. A personalized
thermoplastic mask was used for patient immobilization
and repositioning. All CT scans, extending from the top of
the skull to the third cervical vertebrae, were acquired with
1–3 mm slice thickness and imported in the iPlan stereo-
tactic treatment planning system (Brainlab Ag, Feldkirchen,
Germany). An automatic rigid co-registration was per-
formed for all patients. Clinical target volume (CTV) was
generated by adding an isotropic margin of 10 mm to the
abnormality on preoperative enhanced contrast T1-MRI.
Attention was paid to include in the CTV the entire surgi-
cal cavity, the residual tumor, if present, and abnormality
FLAIR area detected on postoperative MRI. Organs at risk
delineated were brainstem, optic nerves, chiasm, lenses and
healthy brain. Planning target volume (PTV) was defined as
an isotropic expansion from CTV of 3 mm. We choose to
use 1 cm of margin to generate CTV and 3 mm for PTV
with the aim to reduce the risk of damage on healthy brain
tissue. All plans were optimized on PTV. From 2003 to
2010 plans were processed using 3DCRT; plans were de-
signed for multiple coplanar fixed gantry beams shaped
with the multi-leaf collimator and delivered with Clinac
2100 linear accelerator (Varian Medical System, Palo Alto,
USA). Starting from 2011 to 2014, all patients were treated
with VMAT in the RapidArc form (Varian Medical System,
Palo Alto, USA) using single or multiple full or partial co-
planar or non-coplanar arcs based on an individualized plan
optimization. Plans were optimized aiming to achieve a
PTV coverage of D95% > 95 %. All patients were treated on
a TrueBeam linear accelerator (Varian Medical System, Palo
Alto, USA).
Evaluation of treatment plans
The quantitative evaluation of the treatment plans was
performed by means of standard dose volume histogram
(DVH) analysis. A number of relevant metrics were
scored and assessed for all target volumes and OARs.
These included V95, V107, D99 %, homogeneity index (HI)
defined as HI = (D5%–D95 %)/Dmean and conformity index
(CI) defined as reported in the RTOG1993 for the target
volumes, together with a number of appropriate Dx% or
VxGy related to the OARs. Average DVH were computed
over the two cohorts of patients for all target and OAR
structures with a dose binning of 0.02Gy. Mean values
of the selected parameters for the two cohorts of pa-
tients were considered.
Outcome evaluation
Clinical outcome was evaluated by neurological examin-
ation and brain MRI performed 1 month after radiation
therapy and then every 3 months. Recurrence was defined
as follows: “in-field recurrence” (IFR) if it was overlapped
with isodose of 95 %, “marginal recurrence” (MR) if it was
overlapped with isodose of 90 %, “outfield recurrence”
(OR) if it was outside of treatment volume and “distant re-
currence” (DR) if it occurred in other brain lobe [17]. MRI
images acquired during follow up were co-registered with
pre-radiation therapy MRI to precisely define the site of
relapse. Response was recorded using the Response
Assessment in Neuro-Oncology (RANO) criteria [18].
Hematologic and non-hematologic toxicities were graded
according to Common Terminology Criteria for Adverse
Events version 4.0.
Statistical analysis
Standard descriptive statistics (mean standard deviation
and cross tabulation analysis) was used to describe the
data general behavior. Survival and recurrence time
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observations were plotted according to the method of
Kaplan and Meier, starting from the date of surgery. The
log-rank test was used to carry out the univariate ana-
lysis, in order to investigate the prognostic role of indi-
vidual variables. Multivariate Cox model was used as a
method to estimate the independent association of a
variable set with overall and progression free survival.
The SPSS statistics package (IBM Corp,Armonk, USA),
version 22, was used for the analysis.
Results
Patients and treatments
From March 2004 to October 2014, 341 consecutive pa-
tients referred to our institution for HGG were included
in this analysis; 124 (36 %) were female and 217 (64 %)
male with a median age of 59 years (range 19–82 years);
251 (73.6 %) patients had a diagnosis of GB, and 90
(26.4 %) patients WHO grade III glioma. All patients
underwent surgery followed by concomitant and adju-
vant chemo-radiotherapy. Complete surgical resection
(CR) was obtained in 115 patients (34 %), subtotal resec-
tion (SR) in 41 patients (12 %), partial resection (PR) in
116 patients (34 %) and biopsy only in 69 patients
(20 %). Incomplete resection or biopsy was performed in
the case of tumors involving eloquent areas. 3DCRT was
performed from 2003 to 2010 in 167 patients (49 %) and
VMAT from 2011 to 2014 in 174 patients (51 %). The
two cohorts, treated with different radiation therapy mo-
dality, 3DCRT vs VMAT, were homogeneous in terms of
patients, tumors characteristics and treatments per-
formed as shown in Table 1.
Dosimetric analysis
Results from the numerical analysis of the two cohorts
of patients for the considered metrics relevant for CTV,
PTV and the various OARs are reported in the Table 2.
The target volumes were comparable in the two groups
of patients: the mean PTV volume for the VMAT pa-
tients was 275 ± 112 cm3 and 203 ± 101 cm3 for the
3DCRT ones. The coverage objective was considered ac-
ceptable in all the cases. The percentage of VMAT plans
fulfilling the V95 % > 95 % objective shows an average
V95 % higher than the 3DCRT ones, where the under-
dosage of the PTV mainly occurred in patients with
PTV located near OARs. Table 2 shows that no signifi-
cant over-dosage was observed with V107 % = 0.47 and
0.09 cm3 for 3DCRT and VMAT respectively. VMAT
technique allowed to achieve a better conformity index
than 3DCRT simultaneously with an improvement of the
homogeneity index. In both cases the difference was sta-
tistically significant. This result means that VMAT plans
resulted in homogeneous irradiation of the target, at
prescription dose while simultaneously improving the
sparing of the surrounding healthy tissues compared to
the older approach. Dose distribution can be visualized
in the DVHs of Fig. 1, showing the PTV and CTV’s
coverage and the OARs sparing. Concerning the OARs,
it is interesting to focus on the healthy brain diagram.
Medium-high doses (V20Gy and V35Gy) are lower for the
VMAT patients while in the low dose region (V3Gy and
V5Gy) 3DCRT plans give better results. Anyhow while
the percentage deviations between VMAT and 3DCRT
values were at maximum around 5 % for the V3Gy in the
low dose region, they increase up to around 11 % for the
V35Gy in the medium-high dose zone, showing a not
negligible medium dose reduction for the VMAT plans.
For what regards the other OARs (lenses, optic nerves,
chiasm, eyes and brainstem), DVHs are obviously
strongly affected by the relative localization of the le-
sions in the brain. VMAT technique allows to obtain in
some cases, in particular for the ipsi-lateral OARs, a
slightly reduction and control of the high doses. On the
other side 3DCRT plans generally show a reduction of
the mean doses as evidenced by the DVHs.
Outcome of patients
Relatively to the entire cohort of patients, 202 (59 %) pre-
sented neurological symptoms before adjuvant chemo-
radiotherapy and 139 (41 %) patients were asymptomatic.
Clinical remission, complete or partial, was obtained in
the vast majority of patients 198/202 (98 %) after treat-
ment. Neurological status worsened in 4 (2 %) patients.
Patients evaluable for the actuarial analysis were 325 be-
cause 16 were not available to follow up. Among evaluable
patients, 215/325 (66 %) relapsed. Recurrence at the same
site of treatment occurred in 187 (57.5 %) and in 18 of
these, it was associated with a distant tumor progression.
Eighteen (5.5 %) patients had only distant progression. In
relation to the type of RT performed, 3DCRT or VMAT,
recurrences occurred in 114/160 (71 %) and 101/165
(61 %) patients respectively. The recurrence was local in
94 (82.5 %), local and distant in 6 (5.2 %) and distant in 14
(12.3 %) for 3DCRT patients, while for VMAT patients, it
was local for 74 (73.2 %), local and distant for 12 (11.8 %)
and distant for 15 (15 %). Details about local site of re-
lapse, “in-field” (IFR), “marginal” (MR) or “out-field”
(OFR) are shown in Table 3. No out-field recurrence was
recorded in our series.
The median follow up time was 1.3 years (range 0–
11.5 years) for the entire cohort, 1.2 years (range 0–11.5) for
the 3DCRTgroup and 1.4 years (range 0–5.1) for the VMAT
one respectively. At the last observation time 76 patients
(23.4 %) were alive and 249 (76.6 %) died.
Table 4 summarizes the actuarial data for the 3DCRT
and VMAT cohorts relatively to overall survival and pro-
gression free survival. For both observables, the two
groups resulted significantly different (p = 0.02 for PFS
and p < 0.01 for OS) as it results also from Fig. 2.
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On univariate analysis, age, gender, Karnofsky per-
formance scale (KPS), histology and EOR were clinical
variables which influence PFS and OS in both groups,
3DCRT and VMAT. Particularly patients with age
<70 years, KPS >80, WHO grade III glioma versus GB,
and undergoing CR/SR, had a better outcome. About
biological markers, isocitrate dehydrogenase 1 (IDH1)
status was available only for patients treated in the last
years and co-deletion were performed only for non GB
patients, the minority of our patients and therefore no
correlation were made between the 2 groups. In relation
to O-6-methylguanine-DNA-methyltransferase (MGMT)
promoter status, it resulted statistically significant for
both groups; patients with methylated MGMT had bet-
ter outcome compared to un-methylated ones. Details
are shown in Table 5. In multivariate analysis only age
Table 1 Patients and treatment characteristics for the two groups
3DCRT VMAT
Number Percent Number Percent
Total 167 49 174 51
Gender
Female 57 34 67 38.5
Male 110 66 107 61.5




Karnosky Performance Status (KPS)
60 6 3 3 2
70 26 16 25 14
80 68 41 52 30
90 44 26 52 30
100 23 14 42 24
Histology
Glioblastoma (GBM) 129 77 122 70
Anaplastic Astrocytoma (AA) 20 12 29 17
Anaplastic Oligoastrocytoma (AOA) 9 5.5 10 6
Anaplastic Oligodendroglioma (AO) 9 5.5 13 7
Isocitrate dehydrogenase (IDH) mutation status
Wild type – – 126 72
Mutated – – 38 22
NA (not available) 167 100 10 6
1p19q codelation
Codeleted 18 11 30 17
Non codeleted 20 12 22 13
NE (not evaluated for GBM pts) 129 77 122 70
O-6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status
Methylated 94 54 107 61
Unmethylated 76 46 67 49
Surgery
Biopsy (B) 47 28 22 13
Partial Resection (PR) 58 35 58 33
Subtotal Resection (SR) 15 9 26 15
Complete Resection (CR) 47 28 68 39
Adjuvant treatment
RT + concomitant CHT+ adjuvant CHT (TMZ) 167 100 174 100
Abbreviations: 3DCRT 3dimensional conformal radiotherapy, VMAT volumetric modulated arc therapy, RT radiotherapy, CHT chemotherapy, TMZ Temozolomide
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did resulted significantly associated to differences in OS
or PFS. All other prognostic factors, significant in uni-
variate, resulted significant also in the multivariate re-
gression (with p < 0.01) for both 3DCRT and VMAT
cohorts.
Toxicity
Perioperative complications occurred in 30 (9.6 %) pa-
tients. Immediate neurological deficits were found in 22
(6.4 %) patients, in 11 cases recovered within 1 months.
No perioperative mortality occurred. All patients were
evaluated for toxicity during RT with concomitant TMZ
and during the adjuvant chemotherapy treatment time.
All patients completed the scheduled RT planning. No
severe hematologic toxicity was recorded during treat-
ment. During adjuvant chemotherapy 9 patients (2.7 %)
had grade III thrombocytopenia, 21 (6.4 %) patients
grade III neutropenia, 6 (1.8 %) patients grade III anemia
and 9 (2.7 %) patients grade IV hematologic toxicity.
Chemotherapy was interrupted in 6 (1.8 %) patients, and
delayed or reduced in 14 (4.3 %) patients. A moderate to
severe fatigue occurred in 48 (15 %) patients. Six pa-
tients had a deep venous thrombosis and 9 a severe lung
infection (pneumonia) resolved with medical therapy.
No symptomatic radio-necrosis has been reported. No
differences were recorded in patients treated with
3DCRT vs those treated with VMAT.
Treatment at progression
Salvage treatment was performed in 122/215 (56.7 %)
patients and consisted in surgery alone in 16, radiation
therapy alone in 6, and second line chemotherapy alone
in 80 patients. A combined treatment was performed in
20 patients; surgery plus chemotherapy in 8, RT plus
chemotherapy (CHT) in 7, and surgery plus RT followed
by CHT in 5 patients. At the last observation time, 30/
57 (52.7 %) patients are died and 27/57 (47.3 %) are
alive. Concerning the two groups of patients, salvage
treatment was performed in 56/112 3DCRT patients and
in 66/103 VMAT patients. It consisted in surgery alone
Table 2 Comparison of dosimetric results for 3DCRT and VMAT plans
3DCRT VMAT P
PTV
V95 % (%) 93.6 ± 10.2 [52.5; 100.0] 97.2 ± 21.8 [32.4; 99.8] ns
V107 % (%) 0.5 ± 0.9 [0; 2.8] 0.1 ± 0.3 [0.0; 1.4] ns
Vol (cm3) 203.1 ± 101.4 [91.2; 490.8] 274.8 ± 112.9 [99.6; 507.7] ns
D99 % (%) 85.4 ± 19.7 [4.37; 97.30] 82.8 ± 23.7 [16.8; 97.2] ns
HI 0.13 ± 0.8 [0.04; 1.21] 0.09 ± 0.04 [0.03; 0.50] 0.04
CI 1.40 ± 0.30 [1.02; 2.09] 1.04 ± 0.02 [1.00; 1.09] <0.01
Brain-PTV
V3Gy(%) 75.0 ± 18.1 [42.0; 100.0] 79.9 ± 14.8 [51.9; 99.4] ns
V5Gy (%) 69.3 ± 18.1 [42.0; 100.0] 72.9 ± 16.3 [46.6; 98.0] ns
V20Gy (%) 35.4 ± 16.1 [14.2; 75.5] 32.6 ± 13.3 [13.9; 53.7] ns
V35Gy (%) 21.6 ± 12.6 [3.5; 48.9] 12.1 ± 5.6 [5.1; 24.1] 0.03
Dmean (Gy) 18.8 ± 7.0 [10.8; 66.4] 16.5 ± 4.8 [9.9; 24.9] ns
D1% (Gy) 58.9 ± 5.1 [39.9; 65.3] 55.9 ± 1.8 [53.4; 59.3] ns
Ipsilateral Lens
D1% (Gy) 6.4 ± 4.5 [0.5; 14.9] 5.3 ± 2.8 [0.6; 13.9] ns
Controlateral Lens
D1% (Gy) 3.6 ± 4.9 [0.4; 19.8] 5.1 ± 4.2 [0.7; 21.1] ns
Ipsilateral Optic Nerve
D1% (Gy) 19.6 ± 19.2 [1.0; 57.2] 25.5 ± 18.2 [0.9; 53.7] ns
Controlateral Optic Nerve
D1% (Gy) 10.1 ± 11.7 [0.7; 47.2] 12.9 ± 8.9 [1.3; 36.6] ns
Chiasm
D1% (Gy) 22.2 ± 18.1 [1.4; 56.7] 32.0 ± 18.6 [1.8; 55.9] 0.02
Brainstem
D1% (Gy) 33.5 ± 18.4 [1.7; 57.3] 40.9 ± 18.0 [4.9; 62.5] 0.04
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in 8, RT alone in 3, CHT alone in 38, and combined
treatment in 7 patients for the 3DCRT group; for the
VMAT group, surgery alone was performed in 6 pa-
tients, RT alone in 3, CHT alone in 42, and combined
treatment in 15. In both groups the chemotherapeutic
agents more frequently used have been fotemustine and
temozolomide, (93 and 87 % of cases respectively).
Discussion
Radiotherapy is usually delivered with 3D-conformal
techniques but several improvements in the technologies
led to more complex delivery technique (IMRT and
VMAT) used to treat different types of solid tumors with
a considerable outcome improvement, allowing to de-
liver dose with excellent conformation around the tumor
and a better sparing of normal structures [14, 15]. Even
though IMRT is now considered a feasible and practical
delivery technique, to date it is not the standard radio-
therapy approach in the treatment of HGG considering
that the most of RT department treat patients using
3DCRT, and many issues are still to be addressed.
Several studies, comparing 3DCRT and IMRT, were
published, with evidence of similar results in terms of
target coverage, dose homogeneity [19–27] and dose
conformity. In the majority of the published papers, an
overall benefit using IMRT was recorded but mainly, dif-
ferences are minimal, without statistically relevance.
Conversely, a greater sparing of OARs using IMRT has
been highlighted, although to an extent that varies con-
siderably from study to study.
Table 3 Site of recurrence characteristics in relation to different
type of treatments performed 3DCRT or VMAT
3DCRT 160 VMAT 165
Number Percent Number Percent
Recurrence 114 71 101 61
Local (L) 94 82.5 74 73.2
Local + Distant(L + D) 6 5.2 12 11.8
Distant(D) 14 12.3 15 15
In field (IF) 97 97 82 95.4
Marginal(M) 3 3 4 4.6
Outfield (OF) 0 0 0 0
Abbreviations: 3DCRT 3dimensional conformal radiotherapy, VMAT volumetric
modulated arc therapy
Fig. 1 Mean DVH for CTV, PTV and OARs for 3DCRT and VMAT techniques
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The main issue is represented by the integral dose to
healthy brain tissue, which it is still an open question in
relation to different methods used to define the region
of interest (i.e. whole brain-PTV vs whole brain-GTV or
other), the analyzed dosimetric values and the kind of
utilized technique (fixed-field IMRT, helical tomotherapy
or VMAT).
While several experiences comparing fixed-field IMRT
and 3DCRT are available, to our knowledge, only 3 stud-
ies comparing VMAT and 3DCRT were published so far.
Wagner [19] on 14 consecutive glioma patients, showed
a better target coverage in case of PTV close to OARs
using IMRT compared to both VMAT and 3DCRT; the
only convenience of using VMAT was a shorter treat-
ment time, less monitor units and a small V107%. Zach
[24] and similarly Shaffer [20] found that VMAT pro-
vided the best homogeneity coefficient with respect to
3D-CRT and IMRT (p < 0.0003 for all comparison), a
better reduction of mean and maximum dose to OARs
and healthy brain.
Literature data report mainly an equivalence from the
dosimetric point of view between VMAT and 3DCRT
technique for the GB treatments. From our data, VMAT
appears adequate for the treatment of GB. Nevertheless
this study is not a direct comparison between two tech-
niques, since all the patients were not re-planned and
compared with 3DCRT and VMAT, it clearly emerges
that VMAT allows a higher level of control on the high
doses, as expected from this technique. It allows to re-
duce the high doses to the OARs, while the 3DCRT
plans decrease the contribution of the low doses, as it is
clearly evidenced on the healthy brain.
Obviously, dosimetric data are strictly connected to
the localization of the lesions, the proximity to the
OARs and the adopted technique. A further interesting
step might be a study on this group of patients analyzing
the results in relation to the anatomical localization of
the lesion (frontal, temporal and so on). To our know-
ledge no clinical studies comparing 3DCRT and VMAT
are available.
Table 4 Summary of median and 1–3–5 years actuarial data for overall survival and progression free survival for the 3DCRT and
VMAT cohorts
Median time [years] p 1-year 3-years 5-years
Progression free survival
3DCRT 0.99 ± 0.07
(CI95:range 0.9–1.1)
0.02 49.6 ± 4 % 19.1 ± 3.1 % 11.2 ± 2.5 %
VMAT 1.29 ± 0.13
(CI95:range 1.01–1.5)
60.8 ± 3.8 % 29.7 ± 4.6 % 29.7 ± 4.6 %
Overall survival
3DCRT 1.21 ± 0.09 (CI95:1.03–1.3) <0.01 63.3 ± 3.8 % 21.5 ± 3.3 % 10.6 ± 2.5 %
VMAT 1.56 ± 0.09 (CI95:1.37–1.74) 73.4 ± 3.5 % 30 ± 4.6 % 24.2 ± 5.4 %
Fig. 2 Progression Free Survival (PFS) and Overall Survival (OS) in patients with diagnosed High grade Gliomas (HGG) treated with two different
radiation therapy techniques: 3Dimensional conformal radiation therapy (3DCRT) or Volumetric Modulated Arc Therapy (VMAT)
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The main issue is, in our opinion, if the technological
advances could lead a real benefit in the local control
and patients overall survival. For this reason we wanted
evaluate the impact on PFS and OS in patients with di-
agnosed HGG treated in our institution in the last
10 years with 2 different RT modalities. We know that
ours is a retrospective study comparing different radio-
therapy techniques used to treat HGG patients over a
fairly long period of time with the well know limits of
this one. Besides this is one of the larger cohort con-
cerning this issue and some findings recorded should be
promising. The 2 groups evaluated were homogeneous
for patients, tumor characteristics, therapeutic strategies
used at diagnosis and recurrence. In fact, all patients
underwent combined treatment and were treated with
the same salvage treatment at recurrence. The only dif-
ference was the different RT technique used in the 2
group of consecutive patients. The results were highly
satisfactory; in fact the 5 years OS observed was about
10 % in 3DCRT vs 24 % in VMAT group (p < 0.01).
In addition, the same procedure to identify the treat-
ment tumor volume was used and we choose to utilize a
limited margin to generate CTV and PTV compared to
other experience with the aim to spare normal brain tis-
sue as much as possible. Our strategies had proved to be
safe and effective for the low rate of marginal recur-
rences (7/215 recurrences) and for the absence of out-
field relapses.
In relation to the different RT techniques used, the fol-
lowing issues require comment. i) the reduction of
medium-high doses to healthy brain tissue and OARs
might be particularly relevant for the possibility to de-
crease acute and late neurotoxicity influencing quality of
life, above all in long surviving patients. In addition, the
reduction of neurotoxicity could allow a dose escalation,
an employment of hypo-fractionated regimens or in case
of disease recurrence, a second course of RT with lower
risk of side effects; ii) the use of VMAT employed a sig-
nificantly reduction of treatment time in relation to the
high dose rate used with better patients compliance; iii)
a comparable toxicity was recorded using VMAT, not-
withstanding a greater volume received low doses com-
pared to 3DCRT; particularly no interruption of
treatment was needed and no severe subacute toxicity
was observed; iv) however, these clinical findings have to
be considered with caution for the lack of experience
published so far, and for the retrospective nature of our
studies; moreover there seems to be no reasons against
the use of VMAT in the treatments of HGG.
Conclusion
VMAT is superior in terms of dose conformity and spar-
ing of the healthy brain at medium to high doses com-
pared to 3DCRT. In this issue the availability of modern
RT technique that permit a better conformity on the
tumor with maximum sparing of normal organ and tis-
sue could be change the outcome of these patients.
There is no reason against the use of this technique in
GB patients.
Abbreviations
3DCRT, three dimensional conformal radiotherapy; AA, anaplastic astrocytoma;
AO, anaplastic oligo-dendroglioma; AOA, anaplastic oligo-astrocytoma; CHT,
chemotherapy; CI, conformity index; CR, complete resection; CT, computed
tomography; CTV, clinical target volume; DR, distant recurrence; DVH, dose volume
histogram; EOR, extent of resection; FLAIR, fluid-attenuated inversion recovery
imaging; fMRI, functional magnetic resonance imaging; GB, glioblastoma; GTV,
gross tumor volume; HGG, high grade glioma; HI, homogeneity index; IFR, in
field recurrence; IMRT, intensity modulated radiation therapy; IODG1, isocitrate
dehydrogenase 1; KPS, Karnofsky performance scale; MGMT, O-6-
methylguanine-DNA-methyltransferase promoter; MP-RAGE, magnetization-
prepared rapid gradient echo; MR, marginal recurrence; MRI, magnetic resonance
imaging; OAR, organs at risk; OR, outfield recurrence; OS, overall survival; PFS,
progression free survival; PR, partial resection; PTV, planning target volume; RANO,
response assessment in neuro-oncology; RT, radiotherapy; TMZ, temozolomide;
VMAT, volumetric modulated arc therapy; WHO, World health organization
Table 5 Prognostic factors in univariate analysis for progression
free survival (PFS) and Overall Survival (OS). Data reported are the
median survival time for the various groups and the statistical
significance
3DCRT p VMAT p
Overall survival
Agea a: 1.33 ± 0.09
b: 1.06 ± 0.19
0.04 a: 1.59 ± 0.23
b: 1.25 ± 0.21
0.12
KPSb a: 1.06 ± 0.50
b: 2.03 ± 0.53
<0.001 a: 1.03 ± 0.09
b: 2.95 ± 0.51
<0.001
Histologyc a: 3.11 ± 0.60
b: 1.11 ± 0.06
<0.001 a: 3.62 ± 0.39
b: 1.25 ± 0.09
<0.001
EORd a: 1.82 ± 0.31
b: 1.02 ± 0.04
<0.001 a: 2.68 ± 0.44
b: 1.19 ± 0.12
<0.001
MGMTe a: 1.19 ± 0.06
b: 1.48 ± 0.45
0.002 a: 1.23 ± 0.13
b: 1.99 ± 0.27
0.009
Progression free survival
Agea a: 1.10 ± 0.11
b: 0.82 ± 0.25
0.02 a: 1.37 ± 0.24
b: 0.97 ± 0.08
0.06
KPSb a: 0.86 ± 0.04
b: 2.01 ± 0.44
<0.001 a: 0.83 ± 0.09
b: 2.78 ± 0.59
<0.001
Histologyc a: 2.77 ± 0.57
b: 0.93 ± 0.05
<0.001 a: 3.51 ± 0.42
b: 0.99 ± 0.09
<0.001
EORd a: 1.68 ± 0.34
b: 0.83 ± 0.06
<0.001 a: 2.58 ± 0.5
b: 0.92 ± 0.16
<0.001
MGMTe a: 0.95 ± 0.04
b: 1.40 ± 0.36
0.02 a: 0.98 ± 0.12
b: 1.70 ± 0.44
0.02
Abbreviations: 3DCRT 3 dimensional conformal radiotherapy, VMAT volumetric
modulated arc therapy
aa:<70 or b:>70 years
ba:<80 vs b:>80
ca: Grade III glioma(anaplastic astrocytoma, Anaplastic oligodendroglioma,
anaplastic oligoastrocytoma) vs b: Glioblastoma
da: Gross total resection vs b: Partial resection or biopsy
ea: MGMT negative or b: positive





Availability of data and materials
Datasets can be retrieved from authors upon formal request from interested
readers. Datasets cannot be directly shared on public repositories due to the
national personal data protection act.
Authors’ contribution
PN, LB, MS and FP conceived the study. LC, PN and FP drafted the
manuscript. LC, FL, AS performed the analysis. AMA, DGA, CF, MC collected
the data and generated the clinical database. All authors reviewed and
approved the manuscript.
Competing interests
L. Cozzi acts as Scientific Advisor to Varian Medical Systems and is Clinical




Ethical approval and consent to participate
All procedures performed in studies involving human participants were in
accordance with the ethical standards of the institutional and/or national
research committee and with the 1964 Helsinki declaration and its later
amendments or comparable ethical standards.
Humanitas cancer center review board approved the retrospective investigation
upon notification as per the Italian data protection act requirements. At
admission, all patients signed permission to use retrospective data.
Author details
1Radiotherapy and Radiosurgery Department, Humanitas Cancer Center and
Research Hospital, Milan, Italy. 2Department of Neurooncological surgery,
Department of Medical Biotechnology and Translational Medicine, Università
degli Studi di Milano and Humanitas Cancer Center and Research Hospital,
Milan, Italy. 3Department of Neurosurgery, Fondazione IRCCS Ca’ Granda
Ospedale Maggiore Policlinico, Milan, Italy. 4Istituto Clinico Humanitas Cancer
Center, Via Manzoni 56 20089 Rozzano, Milano, Italy.
Received: 3 February 2016 Accepted: 3 June 2016
References
1. Stupp R, Hegi M, Mason W, van den Bent MJ, Tahpoorn M, Janzer R, et al.
Effects of radiotherapy with concomitant and adjuvant temozolomide
versus radiotherapy alone on survival in glioblastoma in a randomized
phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;
10:459–66.
2. Scoccianti S, Magrini S, Ricardi U, Detti B, Krengli M, Parisi S, et al.
Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective
multi center study by the central nervous system study group of AIRO
(Italian association of radiation oncology). Neuro Oncol. 2012;14:798–807.
3. Combs S, Nagy M, Edler L, Rausch R, Bischof M, Welzel T, et al. Comparative
evaluation of radiochemotherapy with temozolomide versus standard-of-
care postoperative radiation alone in patients with WHO grade III astrocytic
tumors. Radiother Oncol. 2008;88:177–82.
4. Brandes A, Nicolardi L, Tosoni A, Gardiman M, Iuzzolino P, Ghimenton C, et
al. Survival following adjuvant PCV or temozolomide for anaplastic
astrocytoma. Neuro Oncol. 2006;8:253–60.
5. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, et al.
NOA-04 randomized phase III trial of sequential radiochemotherapy of
anaplastic glioma with PCV or temozolomide. J Clin Oncol. 2009;35:5874–80.
6. Chan J, Lee S, Fraass B, Normolle d, Greenberg H, Junck L, et al. Survival and
failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. J Clin Oncol. 2002;20:1635–42.
7. Garden A, Maor M, Yung W, Bruner J, Woo s, Moser R, et al. Outcome and
patterns of failure following limited volume irradiation for malignant
astrocytomas. Radiother Oncol. 1991;20:99–110.
8. Hess C, Schaaf J, Kortmann R, Schabet M, Bamberg M. Malignant glioma:
patterns of failure following individually tailored limited volume irradiation.
Radiother Oncol. 1994;30:146–9.
9. Navarria P, Reggiori G, Pessina F, Ascolese A, Tomatis S, Mancosu P, et al.
Investigation on the role of integrated PET/MRI for target volume definition
and radiotherapy planning in patients with high grade glioma. Radiothe
Oncol. 2014;112:425–9.
10. Combs S, Gutwein S, Thilmann C, Debus J, Schulz-Ertner D. Stereotactically
guided fractionated re-irradiation in recurrent glioblastoma multiforme. J
Neurooncol. 2005;74:167–71.
11. Combs S, Widmer V, Thilmann C, Hof H, Debus J, Schulz-Ertner D.
Stereotactic radiosurgery (SRS)-treatment option for recurrent glioblastoma
multiforme (GBM). Cancer. 2005;104:2168–73.
12. Biswas T, Okunieff P, Schell M, Smudzin T, Pilcher W, Bakos R, et al.
Stereotactic radiosurgery for glioblastoma: retrospective analysis. Radiat
Oncol. 2009;4:11.
13. Fuller C, Choi M, Forthuber B, Wang S, Rajagiriyil N, Salter B, et al. Standard
fractionation intensity modulated radiation therapy (IMRT) of primary,
recurrent glioblastoma multiforme. Radiat Oncol. 2007;2:26.
14. Vieillot S, Azria D, Lemanski C, Moscardo C, Gourgou S, Dubois J, et al. Plan
comparison of volumetric modulated arc therapy (RapidArc) and
conventional intensity modulated radiation therapy (IMRT) in anal canal
cancer. Radiat Oncol. 2010;5:92.
15. Clivio A, Fogliata A, Franzetti-Pellanda A, Nicolini G, Vanetti e, Wyttenbach R,
et al. Volumetric modulated arc radiotherapy for carcinomas of the anal
canal: a treatment planning comparison with fixed field IMRT. Radiother
Oncol. 2009;92:118–24.
16. Castellano A, Bello L, Michelozzi C, Gallucci M, Fava E, Iadanza A, et al. Role
of diffusion tensor magnetic resonance tractography in predicting the
extent of resection in glioma surgery. Neuro Oncol. 2012;14:192–202.
17. Ogura K, Mizovaki T, Arakawa Y, Ogura M, Sakanaka K, Miyamoto S, et al.
Initial and cumulative recurrence patterns of glioblastoma after
temozolomide-based chemotherapy and salvage treatment: a retrospective
cohort study in a single institution. Radiat Oncol. 2013;8:97.
18. Wen P, MacDonald D, Reardon D, Cloughesy T, Sorensen A, Galanis E, et al.
Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963–72.
19. Wagner D, Christiansen H, Wolff H, Vorwerk H. Radiotherapy of malignant
gliomas: comparison of volumetric single arc technique (RapidArc), dynamic
intensity-modulated technique and 3D conformal technique. Radiother
Oncol. 2009;93:593–6.
20. Shaffer R, Nichol AM, Vollans E, Fong M, Nakano S, Moiseenko V, et al. A
comparison of volumetric modulated arc therapy and conventional
intensity-modulated radiotherapy for frontal and temporal high-grade
gliomas. Int J Radiat Oncol Biol Phys. 2010;76:1177–84.
21. Hermanto U, Frija E, Lii M, Chang E, Mahajan A, Woo S. Intensity modulated
radiotherapy (IMRT) and conventional three-dimensional conformal
radiotherapy for high-grade gliomas: does IMRT increase the integral dose
to normal brain? Int J Radiat Oncol Biol Phys. 2007;67:1135–44.
22. Narayana A, Yamada J, Berry S, Shah P, Hunt M, Gutin P, et al. Intensity-
modulated radiotherapy in high-grade gliomas: clinical and dosimetrical
results. Int J Radiat Oncol Biol Phys. 2006;64:892–7.
23. Chan M, Schupak K, Burman C, Chui C, Ling C. Comparison of intensity
modulated radiotherapy with three-dimensional conformal radiation
therapy planning for glioblastoma multiforme. Med Dosim. 2003;28:261–5.
24. Zach L, Stall B, Ning H, Ondos J, Arora B, Uma S, et al. A dosimetric
comparison of four treatment planning methods for high grade glioma.
Radiat Oncol. 2009;4:45.
25. Piroth M, Pinkawa M, Holy R, Stoffels G, Demirel C, Attieh C, et al.
Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured
target volume delineation for glioblastoma multiforme—a dosimetric
comparison. Radiat Oncol. 2009;4:57.
26. Lorentini S, Amelio D, Giri M, Fellin f, Meliardo G, Rizzotti A, et al. IMRT or
3D-CRT in glioblastoma? a dosimetric criterion for patient selection. Tech
Canc Res Treat. 2013;5:411–20.
27. MacDonald S, Ahmad S, Kachris S, Vogds B, Derouen M, Gittleman A, et al.
Intensity modulated radiation therapy versus three-dimensional conformal
Navarria et al. BMC Cancer  (2016) 16:362 Page 10 of 10
